[1] Nyi Nyi MP, Gibson TN, Hanchard B, et al. Trends in incidence and age distribution of oral cavity and oropharyngeal squamous cell carcinomas, kingston and st andrew, Jamaica, 1978-2007[J]. West Indian Med J, 2014, 63(2)∶128-133 [2] 李莎莎,周旋,张强,等.STAT3 与miRNA-21 在舌鳞状细胞癌中异常表达的相关性研究[J].中国肿瘤临床,2013,40(6)∶323-327 [3] Mori M, Triboulet R, Mohseni M, et al. Hippo signaling regulates microprocessor and links cell-density-dependent miRNA biogenesis to cancer [J]. Cell, 2014, 156(5)∶893-906 [4] Fu LL, Wen X, Bao JK, et al. MicroRNA-modulated autophagic signaling networks in cancer [J]. Int J Biochem Cell Biol, 2012, 44(5)∶733-736 [5] Liu CJ, Tsai MM, Hung PS, et al. miR-31 ablates expression of the HIF regulatory factor FIH to activate the HIF pathway in head and neck carcinoma [J]. Cancer Res, 2010, 70(4)∶1635-1644 [6] 黄媛媛,周旋,刘爱芹,等.信号传导与转录活化因子3抑制剂WP1066影响人舌鳞状细胞癌增殖与凋亡的研究[J].中华口腔医学杂志,2014,49(5)∶308-313 [7] 张学彦,吕成倩,杜冰,等.FAK在食管癌组织中的表达及临床意义[J].胃肠学和肝病学杂志,2014,23(8)∶866-869 [8] 刘杰,王晓雷,刘琳,等.前哨淋巴结活检在无临床淋巴结转移的早期舌癌临床治疗中的应用价值[J].中华肿瘤杂志,2013,35(6)∶459-462 [9] Wu DW, Chuang CY, Lin WL, et al. Paxillin promotes tumor progression and predicts survival and relapse in oral cavity squamous cell carcinoma by microRNA-218 targeting [J]. Carcinogenesis, 2014, 35(8)∶1823-1829 [10] 杨梅琳, 康玉, 洪珊珊, 等. 不同腹膜后淋巴结转移能力的卵巢癌细胞小RNA(miRNA)表达差异[J].复旦学报(医学版),2014,41(4)∶476-482 [11] Liu CJ1, Lin SC, Yang CC, et al. Exploiting salivary miR-31 as a clinical biomarker of oral squamous cell carcinoma [J]. Head Neck, 2012, 34(2)∶219-224 [12] Chen T, Yao LQ, Shi Q, et al. MicroRNA-31 contributes to colorectal cancer development by targeting factor inhibiting HIF-1α (FIH-1) [J]. Cancer Biol Ther, 2014, 15(5)∶516-523 [13] Zhang T, Wang Q, Zhao D, et al. The oncogenetic role of microRNA-31 as a potential biomarker in oesophageal squamous cell carcinoma [J]. Clin Sci (Lond), 2011, 121(10)∶437-447 [14] Park JS, Kwok SK, Lim MA, et al. STA-21, a promising STAT-3 inhibitor that reciprocally regulates Th17 and Treg cells, inhibits osteoclastogenesis in mice and humans and alleviates autoimmune inflammation in an experimental model of rheumatoid arthritis [J]. Arthritis Rheumatol, 2014, 66(4)∶918-929 [15] Lavecchia A, Di Giovanni C, Novellino E. STAT-3 inhibitors: state of the art and new horizons for cancer treatment [J]. Curr Med Chem, 2011, 18(16)∶2359-2375 [16] Bonner JA, Yang ES, Trummell HQ, et al. Inhibition of STAT-3 results in greater cetuximab sensitivity in head and neck squamous cell carcinoma [J]. Radiother Oncol, 2011, 99(3)∶339-343 |